6 terminated. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Terminated 6 |
| Phase 1 | 1 | Terminated 1 |
Follow Subcutaneous Emphysema: new trials by email Literature Review of Subcutaneous Emphysema trials Research Report on Subcutaneous Emphysema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110 KRRO-110 - Alpha-1 Anti-trypsin Deficiency, AATD | Phase 1 / Phase 2 | Terminated | Korro Bio, Inc. | 42 | 2025-01-13 | 2026-04-17 |
| A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype VX-864 - Alpha-1 Antitrypsin Deficiency | Phase 2 | Terminated | Vertex Pharmaceuticals Incorporated | 14 | 2023-02-23 | 2025-09-08 |
| A Study of Belcesiran in Patients With AATLD Belcesiran, Placebo - Alpha 1-Antitrypsin Deficiency | Phase 2 | Terminated | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 16 | 2021-02-12 | 2026-04-07 |
| Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype VX-814, Placebo - Alpha 1-Antitrypsin Deficiency | Phase 2 | Terminated | Vertex Pharmaceuticals Incorporated | 48 | 2020-01-13 | 2022-02-02 |
| Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus 180 mg/kg Alpha1-PI, 90 mg/kg Alpha1-PI, Placebo - Type 1 Diabetes Mellitus | Phase 2 | Terminated | Grifols Therapeutics LLC | 76 | 2014-03-01 | 2018-09-05 |
| Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency Drug-Carbamazepine (Tegretol XR), Carbamazepine (Tegretol XR) Placebo - Alpha-1-antitrypsin Deficiency, Liver Cirrhosis | Phase 2 | Terminated | Washington University School of Medicine | 20 | 2012-01-01 | 2021-10-12 |
alpha 1-Antitrypsin Deficiency (6) · Diabetes Mellitus, Type 1 (1) · Liver Cirrhosis (1) · Liver Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Digestive System Diseases (6) · Emphysema (6) · Genetic Diseases, Inborn (6) · Lung Diseases (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Respiratory Tract Diseases (6) · Liver Diseases (5) · Autoimmune Diseases (1) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Fibrosis (1) · Glucose Metabolism Disorders (1)
Carbamazepine (1) · Mp alpha1 receptor (1) · alpha 1-Antitrypsin (1)
Vertex Pharmaceuticals Incorporated (2) · Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (1) · Grifols Therapeutics LLC (1) · Korro Bio, Inc. (1) · Washington University School of Medicine (1)
United States (5) · Germany (3) · Ireland (3) · Australia (2) · Canada (2) · New Zealand (2) · United Kingdom (2) · Austria (1) · Belgium (1) · France (1) · Netherlands (1) · Portugal (1) · Spain (1) · Sweden (1)
David H. Perlmutter, M.D. (1) · Thomas Bowman, MD (1)
R21DK092567 (1)